Press releases

TAXUS® Stent shows no additional very late stent thrombosis

OLYMPIA launch phase results show positive outcomes in diabetic patients

Three Boston Scientific subsidiaries will pay a total of $16.75 million and admit no liability

Company plans to announce five-year results from the TAXUS II clinical trial

A live webcast and replay of the September 10 conference session will be available

Amendment to provide the Company additional financial flexibility as it implements initiatives designed to increase shareholder value

Transaction would advance company's plan to divest non-strategic assets and strengthen operating and financial performance

BSC to assume sole control of Pain Management business and emerging indications program, Advanced Bionics principals to purchase Auditory business and drug pump program

Endosurgery group to remain wholly owned by Boston Scientific

Business produces a range of products used to manage fluid and measure pressure during angiography and angioplasty procedures

"We made progress in a number of key areas during the quarter," said Jim Tobin, President and Chief Executive Officer

TAXUS PERSEUS clinical program to evaluate platinum enhanced drug-eluting stent

Successful implantation marks the beginning of the TAXUS PETAL I First Human Use (FHU) Trial

Claims associated with a series of product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant Corporation last year

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2007...

Hardware and software innovations offer new benefits to physicians and patients

Acquisition to bring innovative sensor and wireless communication technology, complementing Company's Cardiac Rhythm Management product line

Deal follows successful four-year exclusive distribution of Prolieve® Thermodilatation System

A live webcast and replay of the June 13 conference session will be available

Article in April 24 edition of JACC highlights shorter procedure time, lower bailout rate

Study seeks to confirm the safety and efficacy of systems in routine clinical practice

Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year

Study highlights importance of antiplatelet therapy compliance

Trial results report no new stent thrombosis after two years in high-risk patient population

Group supports call for limiting greenhouse gas emissions

Company anticipates broad range of clinical results on endoscopic technologies

Single-operator system allows unprecedented visual access to bile duct

Company to release broad range of clinical data on leading drug-eluting stent portfolio

More than 23,000 patients now enrolled in TAXUS OLYMPIA registry

New data provide support for minimally invasive treatment of atrial fibrillation (AF)

Data represents the industry's largest experience with wireless remote monitoring of implantable cardiac devices for one year

Reimbursement granted by National Health Insurance System

RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis

Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice President of Finance and Information Systems

SYNTAX is the first trial to compare the results of drug-eluting stents with those of cardiac surgery in the most complex patient subsets

A live webcast and replay of the May 2 conference session will be available

"I am pleased we came in at the upper end of our ranges for sales and EPS for the quarter," said Jim Tobin, President and Chief Executive Officer

Product provides enhanced control for accessing desired vessel location

A live webcast and replay of the April 23 conference call will be available.

Company has resolved deficiencies in the warning letter issued by the U.S. Food and Drug Administration (FDA) to the Guidant Corporation

Company plans to launch the product after reimbursement approval is granted

Trial is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms

BTK CHILL study demonstrates high rate of limb protection at one year

TAXUS® Express2™ paclitaxel-eluting coronary stent system met its primary endpoint in the treatment of in-stent restenosis

Two-year review of TAXUS Stent safety data presented at ACC

Results reaffirm strength of Boston Scientific's dual drug-eluting stent program

Compliance program is the first of its kind in the medical device industry; is expected to launch in the United States later this year

Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death

Company to host analyst meeting and symposium on drug-eluting stents